Even if it’s not a huge purchase, we think it was good to see that Patrick LePore, the Vice Chairman of the Board of Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) recently shelled out US$72k to buy stock, at US$0.72 per share. While that isn’t the hugest buy, it actually boosted their shareholding by 100%, which is good to see.
The Last 12 Months Of Insider Transactions At Matinas BioPharma Holdings
Notably, that recent purchase by Vice Chairman of the Board Patrick LePore was not the only time they bought Matinas BioPharma Holdings shares this year. Earlier in the year, they paid US$0.95 per share in a US$95k purchase. That means that even when the share price was higher than US$0.67 (the recent price), an insider wanted to purchase shares. It’s very possible they regret the purchase, but it’s more likely they are bullish about the company. To us, it’s very important to consider the price insiders pay for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
In the last twelve months insiders paid US$201k for 237k shares purchased. In the last twelve months Matinas BioPharma Holdings insiders were buying shares, but not selling. Their average price was about US$0.85. These transactions suggest that insiders have considered the current price attractive. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Our data indicates that Matinas BioPharma Holdings insiders own about US$9.7m worth of shares (which is 8.9% of the company). We do generally prefer see higher levels of insider ownership.
What Might The Insider Transactions At Matinas BioPharma Holdings Tell Us?
It is good to see recent purchasing. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss last year, which makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Matinas BioPharma Holdings stock. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Matinas BioPharma Holdings.
Of course Matinas BioPharma Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.